PD-L1-Expressed Exosome Modification Service

Programmed death-ligand 1 (PD-L1) is an essential immune checkpoint protein broadly expressed on the surface of various tumor cells. PD-L1 binds to PD-1 on T cells, significantly suppressing T cell activation, proliferation, and cytotoxic functions, thereby facilitating immune evasion by tumor cells. Recent studies have established a strong correlation between PD-L1 expression in the tumor microenvironment and the effectiveness of tumor immunotherapy, making therapies targeting the PD-L1/PD-1 signaling axis a current focal point in immunotherapy research.

 

From the mechanism of immune escape mediated by tumor PD-L1 to exosome delivery, valuable insights have been gained. Exosomes, as natural extracellular vesicles, possess excellent biocompatibility and stability. Modifying exosomes with PD-L1 expression represents a novel immunomodulatory strategy. PD-L1-engineered exosomes can specifically target cells, suppress T cell immune activity, and exert immunosuppressive effects, showing significant potential for treating immune-related diseases, preventing organ transplant rejection, and modulating immune microenvironments.

 



Wang, J. et al. Transl Oncol. 2021.

Figure 1. Tumor Cells-Derived Exosomal PD-L1 Inhabit T Cells’ Activation in TME

 

Services at MtoZ Biolabs

MtoZ Biolabs offers a PD-L1-Expressed Exosome Modification Service utilizing advanced bioengineering technology and rigorous quality control measures to achieve stable and efficient expression of PD-L1 on exosome surfaces. Leveraging natural exosomes as carriers ensures enhanced targeting accuracy and biological functionality in vivo. Our service includes but is not limited to:

1. Customized PD-L1 exosome modification solutions

2. Production and purification of PD-L1-modified exosomes

3. Quality control analyses (particle size, concentration, expression level)

4. Functional validation of PD-L1 exosomes (T cell activity inhibition assays)

 

Analysis Workflow

1. Sample submission and preliminary quality assessment

2. Exosome isolation and purification

3. PD-L1 gene construction and vector preparation

4. Stable expression and purification of PD-L1 on exosome surfaces

5. Quality control analysis of modified exosomes (particle size, concentration, expression level)

6. Functional validation of exosomes (in vitro activity tests)

7. Data analysis and report delivery

 



Figure 2. The Workflow of PD-L1-Expressed Exosome Modification Service

 

Service Advantages

1. Efficient Expression: Advanced genetic engineering ensures stable and efficient PD-L1 expression on exosome surfaces.

2. Precise Targeting: Utilizing natural exosomes as carriers enhances specific targeting to tissues or cell types.

3. Rigorous Quality Control: Comprehensive quality control guarantees high purity, stability, and excellent batch-to-batch consistency.

4. Comprehensive Functional Validation: In vitro functional assays provided for thorough biological assessment.

5. Rapid Delivery: Experienced technical team and standardized workflow management ensure timely service delivery.

 

Applications

1. Cancer Immunotherapy Research: Modulating immune activity in the tumor microenvironment to develop novel immunotherapies.

2. Autoimmune Disease Research: Using PD-L1-expressing exosomes to suppress hyperactive immune responses and develop potential treatments.

3. Organ Transplant Rejection Studies: Mitigating post-transplant rejection reactions and prolonging graft survival.

4. Inflammatory Response Regulation: Reducing tissue damage by modulating inflammatory environments via exosomes.

 

MtoZ Biolabs is dedicated to providing efficient, stable, and customized PD-L1 exosome modification services for research institutions, hospitals, and pharmaceutical companies worldwide. With our advanced exosome engineering platform and expert technical support, we aim to provide robust assistance to your research projects, jointly promoting continuous advancements in immunotherapy research and applications.